Longeveron’s (LGVN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Longeveron’s Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($2.83) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.46) EPS.

Separately, Maxim Group reduced their price objective on Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th.

Longeveron Stock Up 3.0 %

Longeveron stock opened at $2.06 on Monday. The company has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $2.13. The firm has a market capitalization of $30.57 million, a price-to-earnings ratio of -0.33 and a beta of 0.36. Longeveron has a 52-week low of $0.77 and a 52-week high of $23.90.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.19. The company had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.34 million. Longeveron had a negative net margin of 967.49% and a negative return on equity of 142.43%. During the same quarter in the prior year, the firm earned ($2.80) EPS. On average, research analysts anticipate that Longeveron will post -3.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Longeveron

Several institutional investors and hedge funds have recently bought and sold shares of LGVN. Renaissance Technologies LLC purchased a new stake in shares of Longeveron during the 2nd quarter valued at approximately $236,000. Geode Capital Management LLC increased its stake in Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after acquiring an additional 97,953 shares during the last quarter. Finally, State Street Corp purchased a new stake in Longeveron in the third quarter valued at $29,000. 10.01% of the stock is currently owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.